Abstract： Objective:To analyze the efficacy and safety of recombinant mutant human tumor necrosis factor(rmhTNF)for malignant pleural effusion of lung cancer.Methods:A total of 62 patients with lung cancer and malignant pleural effusion treated in the department of Hematology and oncology of Shanxi coal Central Hospital from January 2017 to January 2020 were selected, including 33 males and 29 females, aged(71.5±4.3 )years, ranging from 65 to 90 years.The patients were randomly divided into cisplatin group and rmhTNF group with 31 cases in each group.The cisplatin group was treated with cisplatin, and the rmhTNF group was treated with rmhTNF on the basis of cisplatin group.The treatment effect, quality of life after treatment, occurrence of adverse reactions and survival time of the two groups were compared after 4 weeks of treatment.Results:The remission rate[74.2%(23/31)]in rmhTNF group was higher than that in cisplatin group[42.0%(13/31)], and the total quality of life[(70.56±6.71)scores]was better than that in cisplatin goup[(60.38±5.98)scores], the difference was statistically significant( P<0.05). There were 4 adverse reactions in rmhTNF group and 6 adverse reactions in cisplatin group.The progression free survival and overall survival in rmhTNF group were longer than those in cisplatin group( P<0.05). Conclusion:rmhTNF is effective in treating malignant pleural effusion of lung cancer and is worthy of popularization and application.